The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Pharmacotherapy for NASH: Current and emerging
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · cited 1×
“Histological endpoints Histological endpoints to assess response to a therapeutic intervention can be broadly divided into those meeting a numerical reduction in one of two accepted scoring systems: NAFLD Activity Score (NAS) or Steatosis Activity and Fibrosis (SAF) score or the resolution of NASH as determined by a q…”
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationPioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., et al. (2007) · Hepatology · doi:10.1002/hep.21496 · Cited by 3,203
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality
Miller, E. R., Pastor-Barriuso, R., Dalal, D., Riemersma, R. A., Appel, L. J., & Guallar, E. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-1-200501040-00110 · Cited by 2,577
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287 · cited 1×
“Overall, the distinction between those with NAFLD and those with NASH is clinically relevant given that multiple studies have demonstrated that patients with NASH are at higher risk of adverse liver-related outcomes, with the degree of fibrosis contributing most significantly to this increased risk.(3,21,22)”
Bjelakovic, G., Nikolova, D., Gluud, L. L., Simonetti, R. G., & Gluud, C. (2007) · JAMA · doi:10.1001/jama.297.8.842 · Cited by 2,275
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Williams, C. D., Stengel, J., Asike, M. I., Torres, D. M., Shaw, J., Contreras, M., Landt, C. L., & Harrison, S. A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.09.038 · Cited by 2,148
Self-citationKlein, E. A., Thompson, I. M., Tangen, C. M., Crowley, J. J., Lucia, M. S., Goodman, P. J., Minasian, L. M., Ford, L. G., Parnes, H. L., Gaziano, J. M., et al. (2011) · JAMA · doi:10.1001/jama.2011.1437 · Cited by 1,787
Singh, S., Allen, A. M., Wang, Z., Prokop, L. J., Murad, M. H., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.014 · Cited by 1,748
Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
Shah, A. G., Lydecker, A., Murray, K., Tetri, B. N., Contos, M. J., & Sanyal, A. J. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.05.033 · Cited by 1,553
Ratziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Self-citationCusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1774 · Cited by 1,024
Mudaliar, S., Henry, R. R., Sanyal, A. J., Morrow, L., Marschall, H., Kipnes, M., Adorini, L., Sciacca, C. I., Clopton, P., Castelloe, E., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.05.042 · Cited by 931 · cited 1×
“OCA downregulates hepatic glucose and lipid metabolism by downregulating SREPB-1c and reducing endogenous bile acid production, via upregulation of FGF19 which then inhibits CYP7A1, the ratelimiting enzyme for the conversion of cholesterol to bile acids.(81) In addition to these primary metabolic effects, OCA may also…”
Bedossa, P., Poitou, C., Veyrie, N., Bouillot, J.-L., Basdevant, A., Paradis, V., Tordjman, J., & Clement, K. (2012) · Hepatology · doi:10.1002/hep.25889 · Cited by 903
Endpoints and clinical trial design for nonalcoholic steatohepatitis
Sanyal, A. J., Brunt, E. M., Kleiner, D. E., Kowdley, K. V., Chalasani, N., Lavine, J. E., Ratziu, V., & McCullough, A. (2011) · Hepatology · doi:10.1002/hep.24376 · Cited by 750
Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases
Samuel, V. T., & Shulman, G. I. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.002 · Cited by 745 · cited 1×
“Journal of storage via stimulation of lipogenesis and inhibition of lipid oxidation.(63) Mouse models of ACC inhibitors have shown that these agents can reduce liver triglycerides, but were also noted to increase plasma triglycerides.”
Park, C. C., Nguyen, P., Hernandez, C., Bettencourt, R., Ramirez, K., Fortney, L., Hooker, J., Sy, E., Savides, M. T., Alquiraish, M. H., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.10.026 · Cited by 708
Friedman, S. L., Ratziu, V., Harrison, S. A., Abdelmalek, M. F., Aithal, G. P., Caballeria, J., Francque, S., Farrell, G., Kowdley, K. V., Craxi, A., et al. (2018) · Hepatology · doi:10.1002/hep.29477 · Cited by 671 · cited 1×
“02).(97) This impact on fibrosis is being further investigated in a current phase III clinical trial of patients with NASH and fibrosis stage 2–3.”
Self-citationIncreased overall mortality and liver-related mortality in non-alcoholic fatty liver disease
Ong, J. P., Pitts, A., & Younossi, Z. M. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.06.018 · Cited by 638
Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure
Nesto, R. W., Bell, D., Bonow, R. O., Fonseca, V., Grundy, S. M., Horton, E. S., Le Winter, M., Porte, D., Semenkovich, C. F., Smith, S., et al. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.256 · Cited by 585
Loomba, R., Lawitz, E., Mantry, P. S., Jayakumar, S., Caldwell, S. H., Arnold, H., Diehl, A. M., Djedjos, C. S., Han, L., Myers, R. P., et al. (2018) · Hepatology · doi:10.1002/hep.29514 · Cited by 549
Leite, N. C., Salles, G. F., Araujo, A. L. E., Villela‐Nogueira, C. A., & Cardoso, C. R. L. (2009) · Liver International · doi:10.1111/j.1478-3231.2008.01718.x · Cited by 531
PPARs: Fatty acid sensors controlling metabolism
Poulsen, L. L. C., Siersbæk, M., & Mandrup, S. (2012) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2012.01.003 · Cited by 510
Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2
Miura, K., Yang, L., van Rooijen, N., Ohnishi, H., & Seki, E. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00365.2011 · Cited by 503
Loomba, R., Abraham, M., Unalp, A., Wilson, L., Lavine, J., Doo, E., & Bass, N. M. (2012) · Hepatology · doi:10.1002/hep.25772 · Cited by 481
Kim, C.-W., Addy, C., Kusunoki, J., Anderson, N. N., Deja, S., Fu, X., Burgess, S. C., Li, C., Ruddy, M., Chakravarthy, M., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.009 · Cited by 419
CCR2 promotes hepatic fibrosis in mice #
Seki, E., de Minicis, S., Inokuchi, S., Taura, K., Miyai, K., van Rooijen, N., Schwabe, R. F., & Brenner, D. A. (2009) · Hepatology · doi:10.1002/hep.22952 · Cited by 416
Staels, B., Rubenstrunk, A., Noel, B., Rigou, G., Delataille, P., Millatt, L. J., Baron, M., Lucas, A., Tailleux, A., Hum, D. W., et al. (2013) · Hepatology · doi:10.1002/hep.26461 · Cited by 414
Weston, S. R., Leyden, W., Murphy, R., Bass, N. M., Bell, B. P., Manos, M. M., & Terrault, N. A. (2005) · Hepatology · doi:10.1002/hep.20554 · Cited by 364
Fatty Infiltration of Liver in Hyperlipidemic Patients
Assy, N., Kaita, K., Mymin, D., Levy, C., Rosser, B., & Minuk, G. (2000) · Digestive Diseases and Sciences · doi:10.1023/a:1005661516165 · Cited by 360
Dulai, P. S., Sirlin, C. B., & Loomba, R. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.06.005 · Cited by 356
Suspected Nonalcoholic Fatty Liver Disease and Mortality Risk in a Population-Based Cohort Study
Dunn, W., Xu, R., Wingard, D. L., Rogers, C., Angulo, P., Younossi, Z. M., & Schwimmer, J. B. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.02034.x · Cited by 325
Risérus, U., Sprecher, D., Johnson, T., Olson, E., Hirschberg, S., Liu, A., Fang, Z., Hegde, P., Richards, D., Sarov-Blat, L., et al. (2008) · Diabetes · doi:10.2337/db07-1318 · Cited by 325
Lefebvre, E., Moyle, G., Reshef, R., Richman, L. P., Thompson, M., Hong, F., Chou, H.-L., Hashiguchi, T., Plato, C., Poulin, D., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0158156 · Cited by 323
Boettcher, E., Csako, G., Pucino, F., Wesley, R., & Loomba, R. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04912.x · Cited by 318
Gender and racial differences in nonalcoholic fatty liver disease
Pan, J.-J. (2014) · World Journal of Hepatology · doi:10.4254/wjh.v6.i5.274 · Cited by 297
Barreyro, F. J., Holod, S., Finocchietto, P. V., Camino, A. M., Aquino, J. B., Avagnina, A., Carreras, M. C., Poderoso, J. J., & Gores, G. J. (2015) · Liver International · doi:10.1111/liv.12570 · Cited by 294
Roles of PPARs in NAFLD: Potential therapeutic targets
Tailleux, A., Wouters, K., & Staels, B. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.10.016 · Cited by 282
Safadi, R., Konikoff, F. M., Mahamid, M., Zelber-Sagi, S., Halpern, M., Gilat, T., Oren, R., Safadi, R., Konikoff, F. M., Hershkovitz, A., et al. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.038 · Cited by 274
Donati, G., Stagni, B., Piscaglia, F., Venturoli, N., Morselli-Labate, A. M., Rasciti, L., & Bolondi, L. (2004) · Gut · doi:10.1136/gut.2003.027086 · Cited by 233
Dongiovanni, P., Anstee, Q., & Valenti, L. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990381 · Cited by 233
Recent advances in the development of farnesoid X receptor agonists.
Ali, A. H., Carey, E. J., & Lindor, K. D. (2015) · PubMed · doi:10.3978/j.issn.2305-5839.2014.12.06 · Cited by 221
Traber, P. G., Chou, H., Zomer, E., Hong, F., Klyosov, A., Fiel, M.-I., & Friedman, S. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075361 · Cited by 214
Pavlides, M., Banerjee, R., Tunnicliffe, E. M., Kelly, C., Collier, J., Wang, L. M., Fleming, K. A., Cobbold, J. F., Robson, M. D., Neubauer, S., et al. (2017) · Liver International · doi:10.1111/liv.13284 · Cited by 197
Noureddin, M., Yates, K. P., Vaughn, I. A., Neuschwander-Tetri, B. A., Sanyal, A. J., McCullough, A., Merriman, R., Hameed, B., Doo, E., Kleiner, D. E., et al. (2013) · Hepatology · doi:10.1002/hep.26465 · Cited by 196
Bone Loss in Diabetes: Use of Antidiabetic Thiazolidinediones and Secondary Osteoporosis
Lecka-Czernik, B. (2010) · Current Osteoporosis Reports · doi:10.1007/s11914-010-0027-y · Cited by 183
Mahady, S. E., Webster, A. C., Walker, S., Sanyal, A., & George, J. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.03.016 · Cited by 165
Activation of the complement system in human nonalcoholic fatty liver disease†
Rensen, S. S., Slaats, Y., Driessen, A., Peutz‐Kootstra, C. J., Nijhuis, J., Steffensen, R., Greve, J. W., & Buurman, W. A. (2009) · Hepatology · doi:10.1002/hep.23228 · Cited by 165
Sasso, M., Audière, S., Kemgang, A., Gaouar, F., Corpechot, C., Chazouillères, O., Fournier, C., Golsztejn, O., Prince, S., Menu, Y., et al. (2015) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2015.08.008 · Cited by 144
Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis
Friedrich‐Rust, M., Rosenberg, W. M., Parkes, J., Herrmann, E. M., Zeuzem, S., & Sarrazin, C. (2010) · BMC Gastroenterology · doi:10.1186/1471-230x-10-103 · Cited by 143
Bariatric Surgery and Non-Alcoholic Fatty Liver Disease: Current and Potential Future Treatments
Sasaki, A., Nitta, H., Otsuka, K., Umemura, A., Baba, S., Obuchi, T., & Wakabayashi, G. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00164 · Cited by 133
Wu, K., Kuo, P., Su, S., Chen, Y., Yeh, M.-L., Huang, C., Yang, J., Lin, C.-I., Hsieh, M., Hsieh, M., et al. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.12.026 · Cited by 127
Parikh, N. D., Marrero, W. J., Wang, J., Steuer, J., Tapper, E. B., Konerman, M. A., Singal, A. G., Hutton, D. W., Byon, E., & Lavieri, M. S. (2017) · Hepatology · doi:10.1002/hep.29473 · Cited by 126
Self-citationSubichin, M., Clanton, J., Makuszewski, M., Bohon, A., Zografakis, J. G., & Dan, A. (2015) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2014.06.015 · Cited by 124
Nonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment
Fruci, B., Giuliano, S., Mazza, A., Malaguarnera, R., & Belfiore, A. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141122933 · Cited by 117
Fuchs, M. A. (2011) · Journal of Lipids · doi:10.1155/2012/934396 · Cited by 114
Kim, C.-W., Addy, C., Kusunoki, J., Anderson, N. N., Deja, S., Fu, X., Burgess, S. C., Cai, L., Ruddy, M., Chakravarthy, M. V., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.011 · Cited by 112
Knowing What’s Out There: Awareness of Non-Alcoholic Fatty Liver Disease
Ghevariya, V., Sandar, N., Patel, K., Ghevariya, N., Shah, R. N., Aron, J., & Anand, S. (2014) · Frontiers in Medicine · doi:10.3389/fmed.2014.00004 · Cited by 104
Low Awareness of Nonalcoholic Fatty Liver Disease Among Patients at High Metabolic Risk
Wieland, A. C., Mettler, P., McDermott, M. T., Crane, L. A., Cicutto, L. C., & Bambha, K. M. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000075 · Cited by 85
Yaʼacov, A. B., Mizrahi, M., Shabat, Y., Lalazar, G., Adar, T., Wong, V., Muller, B. D., Rawlin, G., & Ilan (2012) · Journal of Inflammation Research · doi:10.2147/jir.s35227 · Cited by 73
Adar, T., Yaʼacov, A. B., Lalazar, G., Lichtenstein, Y., Nahman, D., Mizrahi, M., Wong, V., Muller, B. D., Rawlin, G., & Ilan, Y. (2011) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2011.04511.x · Cited by 70
FILOZOF, C. M., Chow, S., Dimick‐Santos, L., Chen, Y., Williams, R. N., Goldstein, B. J., & Sanyal, A. J. (2017) · Hepatology Communications · doi:10.1002/hep4.1079 · Cited by 64
Lefebvre, E. A., Gottwald, M. D., Lasseter, K. C., Chang, W., Willett, M. S., Smith, P. F., Somasunderam, A., & Utay, N. S. (2016) · Clinical and Translational Science · doi:10.1111/cts.12397 · Cited by 59
Wieland, A. C., Quallick, M., Truesdale, A. E., Mettler, P., & Bambha, K. M. (2013) · Digestive Diseases and Sciences · doi:10.1007/s10620-013-2740-8 · Cited by 51
Nonalcoholic Steatohepatitis and Endpoints in Clinical Trials.
Hannah, W. N., Torres, D. M., & Harrison, S. A. (2016) · PubMed · Cited by 39
Self-citationFatty Liver and Liver Transplantation
Koehler, E. M., Watt, K. D. S., & Charlton, M. (2009) · Clinics in Liver Disease · doi:10.1016/j.cld.2009.07.010 · Cited by 37
BMS-986036 (pegylated FGF21) in patients with non-alcoholic steatohepatitis: a phase 2 study
Sanyal, A. J., Charles, E. D., Neuschwander‐Tetri, B. A., Loomba, R. S., Harrison, S. A., Abdelmalek, M. F., Lawitz, E., Halegoua-DeMarzio, D. L., Dong, Y., Noviello, S., et al. (2017) · Journal of Hepatology · doi:10.1016/s0168-8278(17)30443-9 · Cited by 34
Self-citationHashem, R. M., Hassanin, K. M. A., Rashed, L. A., Mahmoud, M. O., & Hassan, M. G. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370216636719 · Cited by 31
Non-Alcoholic Steatohepatitis (NASH): Risk Factors in Morbidly Obese Patients
Losekann, A., Weston, A. C., Mattos, A. D., Tovo, C. V., Carli, L. D., Espindola, M., Pioner, S. R., & Coral, G. P. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161025552 · Cited by 30
Iwasaki, S., Hamada, T., Chisaki, I., Andou, T., Sano, N., Furuta, A., & Amano, N. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.242651 · Cited by 17
Harrison, S. A., Abdelmalek, M. F., Trotter, J. F., Paredes, A. H., Arnold, H. L., Kugelmas, M., Bashir, M. R., Ling, L., Rossi, S. J., DePaoli, A. M., et al. (2017) · Journal of Hepatology · doi:10.1016/s0168-8278(17)30448-8 · Cited by 16
Self-citationDong, Y. P., Chen, Q., Cui, S. H., & Li, F. Q. (2014) · PubMed · doi:10.3967/bes2014.109 · Cited by 4
Cited by
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease
Ipsen, D. H., Lykkesfeldt, J., & Tveden-Nyborg, P. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2860-6 · Cited by 1,471
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Francque, S. M., Bedossa, P., Ratziu, V., Anstee, Q. M., Bugianesi, E., Sanyal, A. J., Loomba, R., Harrison, S. A., Balabanska, R., Mateva, L., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2036205 · Cited by 801
Self-citationHarrison, S. A., Bashir, M. R., Guy, C. D., Zhou, R., Moylan, C. A., Frias, J. P., Alkhouri, N., Bansal, M. B., Baum, S., Neuschwander-Tetri, B. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32517-6 · Cited by 802
Self-citationEpidemiological Features of NAFLD From 1999 to 2018 in China
Zhou, J., Zhou, F., Wang, W., Zhang, X., Ji, Y., Zhang, P., She, Z., Zhu, L., Cai, J., & Li, H. (2020) · Hepatology · doi:10.1002/hep.31150 · Cited by 678
Metadata
- Authors
- Konerman, M. A., Jones, J. C., & Harrison, S. A.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2018-02
- Volume
- 68
- Issue
- 2
- Pages
- 362-375
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2767673297
- Cited by
- 292
- References
- 78
- FWCI
- 25.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.